Clinical TrialTreatment-Resistant Depression (TRD)PsilocybinActive not recruiting

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (COMP 006)

Phase III, randomised, double-blind, parallel-group study (n=568) comparing two administrations of COMP360 psilocybin at 25 mg, 10 mg and 1 mg in adults with treatment-resistant depression.

Ask Blossom about this trial
Target Enrollment
568 participants
Study Type
Phase III interventional
Design
Randomized, quadruple Blind

Continue exploring

Continue exploring this trial

Move from the registry record to the most relevant public research context.

Compound research: PsilocybinTopic research: Treatment-Resistant Depression (TRD)Research in United States

Detailed Description

International, multi-centre, randomised (2:1:1), parallel-group, double-blind (quadruple-masked) Phase III study assessing efficacy and safety of two administrations of COMP360 (psilocybin) in adults with treatment-resistant depression.

Total planned duration approximately 62 weeks including screening; study includes three parts with follow-up out to 9 weeks (Part A), 26 weeks (Part B) and 52 weeks (Part C) from initial investigational product administration. Psychological support is provided alongside dosing.

Study Protocol

Preparation

sessions

Dosing

2 sessions

Integration

sessions

Therapeutic Protocol

support

Study Arms & Interventions

Psilocybin 25 mg (COMP360)

experimental

COMP360 psilocybin 25 mg with psychological support (two administrations).

Interventions

  • Psilocybin25 mg
    via Oral• two administrations• 2 doses total

    COMP360 administered under supportive conditions

Psilocybin 10 mg (COMP360)

experimental

COMP360 psilocybin 10 mg with psychological support (two administrations).

Interventions

  • Psilocybin10 mg
    via Oral• two administrations• 2 doses total

    COMP360 administered under supportive conditions

Psilocybin 1 mg (COMP360)

active comparator

COMP360 psilocybin 1 mg active comparator with psychological support (two administrations).

Interventions

  • Psilocybin1 mg
    via Oral• two administrations• 2 doses total

    Low-dose active comparator; COMP360

Participants

Ages
18 – 65
Sexes
Male & Female

Inclusion Criteria

  • Key Inclusion Criteria:
  • 1. Aged ≥18 years at Screening
  • 2. Major depression without psychotic features (single or recurrent episode as informed by DSM-5)
  • 3. If the current major depressive episode is the participant's first lifetime episode of depression, the length of the current episode must be ≥3 months and ≤2 years at Screening
  • 4. MADRS total score ≥20 at Screening and Baseline
  • 5. TRD, defined as failure to respond to an adequate dose and duration of two, three, or four different pharmacological treatments for the current episode as determined through the MGH-ATRQ
  • 6. At Screening, agreement to discontinue all prohibited medications

Exclusion Criteria

  • Key Exclusion Criteria:
  • 1. Prior or ongoing bipolar disorder, any psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder (unless substance induced or due to a medical condition), antisocial personality disorder
  • 2. Lifetime paranoid, schizoid, schizotypal, histrionic, narcissistic personality disorder, or any ongoing serious psychiatric comorbidity
  • 3. Borderline personality disorder as demonstrated by medical history or MINI plus module
  • 4. Ongoing PTSD, OCD, or anorexia nervosa
  • 5. Psychiatric inpatient within the past 12 months prior to Screening
  • 6. Use of ECT, DBS, or VNS during the current depressive episode
  • 7. TMS within the past six months prior to Screening
  • 8. Current enrolment in a psychological therapy programme that will not remain stable for the duration of the study; psychological therapies cannot have been initiated within 30 days prior to Screening
  • 9. Exposure to COMP360 psilocybin therapy prior to Screening

Study Protocol, Arms & Participants

Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.

See Pro Plans

Study Details

Study Team

Sponsors & Collaborators

Locations

Lighthouse Psychiatry Scottsdale — Gilbert, Arizona, United States
Clinical Innovations, Inc. — Bellflower, California, United States
M3 Wake Research — Encino, California, United States
The Regents of the University of California - San Diego — La Jolla, California, United States
Kadima Neuropsychiatry Institute — La Jolla, California, United States
CalNeuro Research Group, Inc — Los Angeles, California, United States
Catalina Research Institute, LLC — Montclair, California, United States
Piedmont Hospital Neuroscience Centre — Oakland, California, United States
ATP Clinical Research, Inc. — Orange, California, United States
CITrials — Riverside, California, United States
Lumos Clinical Research Center — San Jose, California, United States
Syrentis Clinical Research — Santa Ana, California, United States
Stanford University — Stanford, California, United States
ASCLEPES Research Centers — Thousand Oaks, California, United States
Pacific Clinical Research Management Group, LLC — Upland, California, United States
Innovative Clinical Research, Inc. — Lauderhill, Florida, United States
Central Miami Medical Institute, LLC — Miami, Florida, United States
Behavioral Clinical Research, Inc. — Miami Lakes, Florida, United States
Health Synergy Clinical Research — Okeechobee, Florida, United States
Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare — Orlando, Florida, United States
APG Research, LLC- Advanced Psychiatric Group — Orlando, Florida, United States
University South Florida — Tampa, Florida, United States
Stedman Clinical Trials — Tampa, Florida, United States
Health Synergy Clinical Research, LLC — West Palm Beach, Florida, United States
Atlanta Center for Medical Research — Atlanta, Georgia, United States
iResearch Atlanta — Decatur, Georgia, United States
Rush University Medical Center — Chicago, Illinois, United States
Uptown Research Institute, LLC — Chicago, Illinois, United States
Psychiatric Medicine Associates — Skokie, Illinois, United States
Harvard Medical School - McLean Hospital — Belmont, Massachusetts, United States
Adams Clinical - Boston (Copley Clinical) — Boston, Massachusetts, United States
University of Massachusetts Medical School — North Worcester, Massachusetts, United States
Adams Clinical - Boston — Watertown, Massachusetts, United States
Michigan Clinical Research Institute PC — Ann Arbor, Michigan, United States
University Of Michigan Comprehensive Depression Center — Ann Arbor, Michigan, United States
Institute for Integrative Therapies — Eden Prairie, Minnesota, United States
St. Charles Psychiatric Associates - Midwest Research Group — Saint Charles, Missouri, United States
Alivation Research, LLC. — Lincoln, Nebraska, United States
Hassman Research Institute — Berlin, New Jersey, United States
Princeton Medical Institute — Princeton, New Jersey, United States
Bio Behavioral Health — Toms River, New Jersey, United States
Dent Neurosciences Research Center, Inc. — Amherst, New York, United States
Fieve Clinical Research, Inc — New York, New York, United States
Spectrum Neuroscience and Treatment Institute — New York, New York, United States
Adams Clinical - New York — New York, New York, United States
New York State Psychiatric Institute — New York, New York, United States
Richmond Behavioral Associates — Staten Island, New York, United States
Adams Clinical - New York — The Bronx, New York, United States
University of Cincinnati, Department of Psychiatry & Behavirol Neuroscience — Cincinnati, Ohio, United States
Cleveland Clinic - Lutheran Hospital — Cleveland, Ohio, United States
The Ohio State University — Columbus, Ohio, United States
Suburban Research Associates — Media, Pennsylvania, United States
The University of Texas at Austin - Dell Medical School — Austin, Texas, United States
Houston Clinical Trials, LLC — Bellaire, Texas, United States
Relaro Medical Trials — Dallas, Texas, United States
Center for Depression Research and Clinical Care — Dallas, Texas, United States
North Texas Clinical Trials — Fort Worth, Texas, United States
Brain Health Consultants and TMS Center — Houston, Texas, United States
HCA Healthcare Research Institute - Medical City Green Oaks Hospital — Plano, Texas, United States
Cedar Clinical Research — Draper, Utah, United States
The University of Utah - Huntsman Mental Health Institute — Salt Lake City, Utah, United States
Seattle Neuropsychiatric Treatment Center — Seattle, Washington, United States
Diex Recherche Sherbrooke Inc. — Québec, B.C., Canada
Medical Arts Health Research Centre, Kamloops — Kamloops, British Columbia, Canada
Okanagan Clinical Trials — Kelowna, British Columbia, Canada
Medical Arts Research Group - Penticton — Penticton, British Columbia, Canada
Chatham-Kent Clnical Trials Centre — Chatham, Ontario, Canada
St. Michael's Hospital — Toronto, Ontario, Canada
Centre for Addiction and Mental Health (CAMH) — Toronto, Ontario, Canada
Centre for Neurology Studies — Vancouver, Canada
Medical Arts Research Group — Vancouver, Canada
National Institute of Mental Health — Klecany, Czechia
Neuroterapie KH Sro — Kutná Hora, Czechia
Psychiatric Ambulance — Ostrava, Czechia
A-Shine s.r.o. — Pilsen, Czechia
Psychedelicka klinika, s.r.o. — Prague, Czechia
Institut Neuropsychiatricke Pece — Prague, Czechia
Aalborg Universitetshospital-Psykiatrien Region Nordjylland — Aalborg, Denmark
Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau — Nîmes, France
Universite Paris VI Pierre et Marie Curie - Hopital de La Salpetriere - Centre Emotion - USR 3246 (CNRS UMR 7593) — Paris, France
Centre Hospitalier Sainte Anne - Clinique des Maladies Mentales et de l'Encephale (CMME) — Paris, France
Ghu-Centre Hospitalier Sainte Anne, Centre de Recherche Clinique — Paris, France
Charite-Universitaetsmedizin Berlin — Berlin, Germany
Johann Wolfgang Goethe-Universitaet Frankfurt am Main - Klinik fuer Psychiatrie, Psychosomatik und Psychotherapie — Frankfurt, Germany
ZiP Campus Luebeck — Lübeck, Germany
Tallaght University Hospital — Dublin, Ireland
La Nua Day Hospital Mental Health Centre — Galway, Ireland
University Medical Center Groningen — Groningen, Netherlands
Leids Universitair Medisch Centrum (LUMC) (Leiden University Medical Center) - Leiden Institute for Brain and Cognition (LIBC) — Leiden, Netherlands
Universitair Medisch Centrum Utrecht (UMC Utrecht) — Utrecht, Netherlands
Promente - Ośrodek Badań Klinicznych — Bydgoszcz, Poland
Uniwersyteckle Centrum Kliniczne, Klinika Psychiatrii Doroslych — Gdansk, Poland
Centrum Badan Klinicznych PI-House Sp. z o.o. — Gdansk, Poland
Hospital Clinic de Barcelona — Barcelona, Spain
Parc Sanitari Sant Joan de Deu (Sant Joan de Deu Serveis de Salut Mental) — Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain
FIDMAG Hermanas Hospitalarias — Sant Boi de Llobregat, Spain
Hospital Universitario Río Hortega de Valladolid — Valladolid, Spain
Hospital Provincial de Zamora - Servicio de Psiquiatria — Zamora, Spain
Vuxenpsykiatrimottagningen — Landskrona, Sweden
Lunds Universitet - Medicinska Fakulteten (Lund University Faculty of Medicine) — Lund, Sweden
ClinSmart Sweden AB — Solna, Sweden
Hälsoklustret — Stockholm, Sweden
Cornwall Partnership NHS Foundation Trust — Bodmin, Cornwall, United Kingdom
Abraham Cowley Unit - Surrey and Borders Partnership NHS Foundation Trust — Chertsey, United Kingdom
St. Pancras Clinical Research — Chester, United Kingdom
Grounded Research Hub - Rotherham Doncaster & South Humber NHS Foundation Trust — Doncaster, United Kingdom
Clinical Research Facility, Royal Devon and Exeter Hospital — Exeter, United Kingdom
Fulbourn Hospital - Cambridgeshire And Peterborough NHS Foundation Trust — Fulbourn, United Kingdom
St. Pancras Clinical Research — London, United Kingdom
King's College London - Institute of Psychiatry, Psychology — London, United Kingdom
Clerkenwell Health — London, United Kingdom
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust - Wolfson Research Centre — Newcastle, United Kingdom
University Of Nottingham/Nottinghamshire Healthcare Trust, Institute Of Mental Health — Nottingham, United Kingdom
The Warneford Hospital- NIHR Clinical Research Facility — Oxford, United Kingdom
Sheffield Health and Social Care NHS Foundation Trust — Sheffield, United Kingdom

Recent activity

  • StartedEfficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (COMP 006) (NCT05711940, psilocybin)

Your Personal Research Library

Go Pro to save trials, add notes, rate research, and organize custom shelves.

See Pro Plans